Monopar Therapeutics Inc
MNPR68.770USD
-2.010-2.84%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
458.21MMarket Cap
LossP/E TTM
More Details of Monopar Therapeutics Inc Company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Monopar Therapeutics Inc Info
Ticker SymbolMNPR
Company nameMonopar Therapeutics Inc
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Number of employees16
Security typeOrdinary Share
Fiscal year-endDec 19
Address1000 Skokie Blvd Ste 350
CityWILMETTE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code60091-1146
Phone18473880349
Websitehttps://www.monopartx.com/
Ticker SymbolMNPR
IPO dateDec 19, 2019
CEORobinson (Chandler D)
Company Executives of Monopar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Other
48.28%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
19.26%
Adage Capital Management, L.P.
9.86%
Gem Pharmaceuticals LLC
9.14%
RA Capital Management, LP
7.65%
AstraZeneca PLC
5.80%
Other
48.28%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
27.20%
Hedge Fund
19.02%
Corporation
19.01%
Investment Advisor
9.43%
Venture Capital
9.00%
Individual Investor
4.78%
Research Firm
0.24%
Pension Fund
0.07%
Bank and Trust
0.06%
Other
11.17%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
1.17M
17.73%
+37.96K
+3.35%
Jun 30, 2025
Adage Capital Management, L.P.
599.20K
9.06%
--
--
Jun 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.24%
--
--
Apr 04, 2025
RA Capital Management, LP
511.21K
7.73%
--
--
Jun 30, 2025
AstraZeneca PLC
387.33K
5.86%
+387.33K
--
Oct 23, 2024
Tactic Pharma LLC
272.03K
4.11%
-550.23K
-66.92%
Sep 24, 2025
The Vanguard Group, Inc.
86.49K
1.31%
+31.25K
+56.59%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
183.97K
2.78%
+175.22K
+2003.49%
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Micro-Cap ETF
0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.04%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.06%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.04%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
FAQs
Who are the top five shareholders of Monopar Therapeutics Inc?
The top five shareholders of Monopar Therapeutics Inc are:
Janus Henderson Investors holds 1.17M shares, accounting for 17.73% of the total shares.
Adage Capital Management, L.P. holds 599.20K shares, accounting for 9.06% of the total shares.
Gem Pharmaceuticals LLC holds 611.08K shares, accounting for 9.24% of the total shares.
RA Capital Management, LP holds 511.21K shares, accounting for 7.73% of the total shares.
AstraZeneca PLC holds 387.33K shares, accounting for 5.86% of the total shares.
Janus Henderson Investors holds 1.17M shares, accounting for 17.73% of the total shares.
Adage Capital Management, L.P. holds 599.20K shares, accounting for 9.06% of the total shares.
Gem Pharmaceuticals LLC holds 611.08K shares, accounting for 9.24% of the total shares.
RA Capital Management, LP holds 511.21K shares, accounting for 7.73% of the total shares.
AstraZeneca PLC holds 387.33K shares, accounting for 5.86% of the total shares.
What are the top three shareholder types of Monopar Therapeutics Inc?
The top three shareholder types of Monopar Therapeutics Inc are:
Janus Henderson Investors
Adage Capital Management, L.P.
Gem Pharmaceuticals LLC
Janus Henderson Investors
Adage Capital Management, L.P.
Gem Pharmaceuticals LLC
How many institutions hold shares of Monopar Therapeutics Inc (MNPR)?
As of 2025Q3, 99 institutions hold shares of Monopar Therapeutics Inc, with a combined market value of approximately 3.34M, accounting for 50.46% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -32.45%.
What is the biggest source of revenue for Monopar Therapeutics Inc?
In --, the -- business generated the highest revenue for Monopar Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
